Camilleri M, Kerstens R, Rykx A, Vandeplassche L
Abbreviations AD: Alzheimers disease BBB: bloodbrain barrier GLP-1: glucagon-like peptide-1 GLP-1R(s): GLP-1 receptor(s) GLP-1RA(s): GLP-1 receptor agonists NDD: neurodegenerative diseases PD: Parkinsons disease T2DM: type 2 diabetes mellitus REFERENCES Knudsen LB, Lau J (2019) The Discovery and Development of Liraglutide and Semaglutide
Understanding the molecular structures of these drugs, their half-lives, dosing frequencies, and side effects is crucial for us to make informed decisions about which treatment would be most effective for each patient
The absence of leg cramps from official labeling does not definitively rule out a connection, as post-marketing experience sometimes reveals adverse effects not detected in pre-approval trials due to sample size limitations, duration of follow-up, or patient population differences
Lets be clear about expectations